Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Dual inhibition of EGFR and PI3K with a single drug

Nature Cancer volume 5, pages 1131–1133 (2024)Cite this article

Subjects

Precision medicine holds immense promise for treating individuals with cancer. A new study unveils MTX-531 — a drug that can inhibit two signaling proteins, EGFR and PI3K — which was developed through innovative computational drug design and offers new hope for more-effective and better-tolerated cancer treatments.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: MTX-531 — a dual inhibitor of PI3K and EGFR — overcomes resistance mechanisms that frequently occur in standard-of-care treatments.

References

  1. Whitehead, C. E. et al. Nat. Cancer https://doi.org/10.1038/s43018-024-00781-6 (2024).

  2. Johnson, M., Garassino, M. C., Mok, T. & Mitsudomi, T. Lung Cancer 170, 41–51 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Chhouri, H., Alexandre, D. & Grumolato, L. Cancers (Basel) 15, 504 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Rehmani, H. S. & Issaeva, N. Ann. Transl. Med. 8, 813 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Xie, Y.-H., Chen, Y.-X. & Fang, J.-Y. Signal Trans. Targeted Ther. 5, 22 (2020).

    Article  CAS  Google Scholar 

  6. Diniz, C. H. D. P., Henrique, T., Stefanini, A. C. B., De Castro, T. B. & Tajara, E. H. Oncol. Rep. 51, 80 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tankova, T. et al. Cancers 14, 1598 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Chauhan, A. F. & Cheson, B. D. Cancer Manag. Res. 13, 677–692 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Chandarlapaty, S. et al. Cancer Cell 19, 58–71 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Klinghammer, K. et al. Oncotarget 11, 3688–3697 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Elkabets, M. et al. Cancer Cell 27, 533–546 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Razak, A. R. A. et al. Target. Oncol. 18, 853–868 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Marret, G. et al. Invest. New Drugs 39, 1641–1648 (2021).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by the National Cancer Institute, grant number ZIA BC 011691.

Author information

Authors and Affiliations

  1. Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, USA

    Meghri Katerji, Maxine R. Rubin & John Brognard

Authors
  1. Meghri Katerji
    View author publications

    Search author on:PubMed Google Scholar

  2. Maxine R. Rubin
    View author publications

    Search author on:PubMed Google Scholar

  3. John Brognard
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to John Brognard.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Katerji, M., Rubin, M.R. & Brognard, J. Dual inhibition of EGFR and PI3K with a single drug. Nat Cancer 5, 1131–1133 (2024). https://doi.org/10.1038/s43018-024-00806-0

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-024-00806-0

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer